Palantir CEO Says Its LLM ‘More Like A Chemistry Experiment’ Being Refined For Business; Decodes Defense Spending, 2024 Election At AIPCon 4
Karp said that historically, the party in the White House has had little impact on Palantir.
GOP Lawmakers Urge Ban On Chinese Battery Suppliers Tied To Ford, Volkswagen Over Forced Labor Allegations
CATL is the world's largest electric car battery manufacturer and a partner of Ford, while Gotion is a battery company partially owned by Volkswagen.
Car-Rental Firm Hertz Reportedly Seeks $700M Lifeline As EV Strategy Stalls
The company is looking to remove 30,000 electric vehicles from its fleet, significantly higher than the number announced earlier this year.
Apple Could Introduce Passwords App At WWDC 2024 To Challenge 1Password And LastPass
Apple will reportedly unveil a new app called "Passwords" at the WWDC on June 10, designed to simplify and secure the login process by generating, storing, and managing passwords across its devices.
Robinhood CEO Says Exchange Is Ready For Roaring Kitty Livestream Surge: ‘We Are Prepared’ For GameStop Frenzy
Robinhood CEO Vlad Tenev assures preparedness for GameStop surge and announces Bitstamp acquisition. Company aims for international expansion and entry into institutional business.
Netflix Reality Show Games And Chill? Streaming Giant Sees Success From Interactive Games Based On Hit Shows
Netflix is ready to combine reality television and video games in a new push to grab new subscribers and keep the ones it has.
Italy Probes European Pharma Giants Novartis, Roche Over Eye Drug Competition Allegations
Italy's antitrust authority is investigating Novartis and Roche's Genentech for allegedly delaying the Italian market launch of Byooviz, a Samsung Bioepis biosimilar of Lucentis.
Why Is Mid-Cap Cancer-Focused Replimune Stock Trading Higher On Thursday?
Replimune reported that the IGNYTE clinical trial of RP1 plus nivolumab in anti-PD1 failed melanoma showed a 33.6% response rate, with all responses lasting over six months. The treatment was well-tolerated.
Eli Lilly’s Alzheimer’s Drug, Donanemab Faces FDA’s Adcomm Vote Next Week On Data, Risk Profile
The FDA's advisory committee will review Eli Lilly's Phase 3 study on donanemab for Alzheimer's disease on June 10. This review assesses the drug's benefit-risk profile based on significant efficacy results in cognition and daily function.
Cathie Wood Remains Bullish On AI Investments Despite Nvidia Stock Adjustments
Cathie Wood of Ark Investment Management remains bullish on AI investments despite reducing Nvidia Corp (NASDAQ
) shares before their rise. Speaking at the Greenwich Economic Forum, Wood emphasized Ark's focus on emerging tech.